Nanosanguis S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-01-12
Share capital
4,469,187.00 PLN
Average employment (people)
26 (2025)
Activity description

Nanosanguis is a biotechnology company focused on utilizing nanotechnology in medicine, specifically in the fields of transplantation and transfusion. It aims to increase the availability of organs for transplantation by developing innovative organ perfusion systems and a safe, effective blood substitute. The company also seeks to enhance organ preservation methods and expand the donor pool by utilizing kidneys from donors after circulatory death.

Registered address
ul. Rakowiecka 36, 02-532 Warszawa, Poland
Email
Phone
Electronic delivery address
AE:PL-40575-90804-VATFB-13

Financials

Revenue history (in k)

Financial insight

  • Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.

From the notes

Profit allocationLoss to be covered
Management board pay$200,904
Deferred tax assets$3,885,021
Shareholders
  • NanoGroup S.A. 3.37%
  • osoba fizyczna 0.32%
  • osoba fizyczna 0.06%
  • osoba fizyczna 0.02%

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 21 days late). All were audited by a statutory auditor.

  • 202514/07/2026
  • 202414/07/2025
  • 202305/08/2024
  • 202206/07/2023
  • 202130/06/2022
  • 202002/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 41%
Top 42%
City · Warszawa30,250 / 56,772
Top 53%
Voivodeship · Mazowieckie42,191 / 76,953
Top 55%
Country · Poland167,200 / 297,266
Top 56%

Results vs industry

Revenue
This companyUSD 192.70kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -1.04mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 1.07mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 6.18mMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Organ perfusion research
  • Organ perfusion system
  • Organ regeneration
  • Blood substitute preparation
  • Nanomedicine technologies

Website technology

Online shop
  • WooCommerce
Website
  • WordPress
Analytics and marketing
  • Google Analytics

Authorized Representatives

Przemysław Daniel Mazurek age 50 – President of the Management Board
Zbigniew Jerzy Posłajko age 56 – Attorney-in-fact (sole)
Piotr Paweł Mierzejewski age 62 – Management Board Member

Manner of representation

In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.

Supervisory board

Robert Artur Dziubłowski age 63 – Supervisory Board Member
Stefan Marcin Bogusławski age 67 – Supervisory Board Member
Jerzy Krzysztof Garlicki age 61 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2016-01-29.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jan 19, 2017Commercial Companies Code notice
Apr 19, 2016Commercial Companies Code notice

Public aid

17 public aid cases recorded, with a total value of $9,945,966.

PurposeGross amount
Aid for research and development projects: industrial research
$3.9M
Aid for research and development projects: experimental development
$1.7M
Aid for research and development projects: industrial research
$507K

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $7,415,789.

ProjectEU co-financing
NanOX 4 Kidney – next-generation kidney perfusion fluid based on a synthetic oxygen carrier
$5.6M
Development of a significantly improved device for normothermic organ perfusion in the field of transplantation.
$82,825
OrganFarm – a system for the long-term storage of organs ex vivo
$1.3M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Scope Fluidics S.A.
Nanogroup S.A.
Famicordtx S.A.
Vaxican sp. z o.o.
Medicofarma Biotech S.A.
Bactrem sp. z o.o.
Biotts S.A.
Personather sp. z o.o.
Orphinic Scientific S.A.
DR Joanna Sanford sp. k.

Change history

DateEvent
2025-09-16Switch to PKD 2025
2025-01-24Share capital increase
2024-07-10Share capital increase
2024-02-13Share capital increase
2023-06-12Share capital increase

FAQ

Last updated: 2026-07-17